Lumibird Medical announces the launch of the C.DIAG®, a new-generation dry eye diagnostic aid platform with integrated AI algorithms. This new component of the C.SUITETM offer enables healthcare professionals to diagnose, treat and educate dry eye patients and positions Lumibird Medical as a major player in this growing market.
Dry Eye Disease (DED) is a public health problem that affected 1.4 billion people in 2021* and represents today the second cause of ophthalmologic consultations after visual acuity*. The management of DED has increasingly become a challenge in many specialties such as glaucoma, refractive & cataract surgeries and contact lenses.
The manufacturer Quantel Medical, Lumibird Medical group, is launching C.DIAG®, an automatic Dry Eye diagnostic aid platform.
"C.DIAG is an automated diagnostic aid platform, the most complete on the market, integrating multiple exams as transillumination meibography and an autofocus HD camera for unrivalled image quality and automatic, accurate and reproducible results. The incorporated Artificial Intelligence is based on algorithms derived from more than one million clinically validated images."
Jean-Marc Gendre, CEO of Lumibird Medical
Delegates attending the SFO Congress in Paris from May 04th to May 06th will have the opportunity to discover the C.SUITETM on the Lumibird Medical stand.
For more information about C.DIAG®, visit our website for healthcare professionnals:
* : Market Scope© Market Study: 2021 Dry Eye Products Market Report, global analysis for 2020 to 2026